Research programme: serotonin 2C receptor agonists - Bright Minds Biosciences
Alternative Names: 5-HT2C agonists - Bright Minds BiosciencesLatest Information Update: 28 Mar 2025
At a glance
- Originator Bright Minds Biosciences
- Class Antidementias; Antiepileptic drugs; Behavioural disorder therapies; Drug withdrawal therapies
- Mechanism of Action 5-HT2C serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Binge-eating disorder; Epilepsy; Opioid-related disorders
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada
- 28 Mar 2025 No recent reports of development identified for preclinical development in Binge-Eating-Disorder in Canada
- 28 Mar 2025 No recent reports of development identified for preclinical development in Epilepsy in Canada